337969-56-9

Basic information

• Product Name: (2S)-1-{[1-(triphenylmethyl)imidazol-4-yl]carbonyl}-3-(1,2,3,4-tetrahydroisoquinolyl)-N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-(methylethyl)-2-oxoethyl]carboxamide
• Synonyms: (2S)-1-{[1-(triphenylmethyl)imidazol-4-yl]carbonyl}-3-(1,2,3,4-tetrahydroisoquinolyl)-N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-(methylethyl)-2-oxoethyl]carboxamide
• CAS NO: 337969-56-9
• Molecular Weight: 720.871
• Mol File: 337969-56-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S)-1-{[1-(triphenylmethyl)imidazol-4-yl]carbonyl}-3-(1,2,3,4-tetrahydroisoquinolyl)-N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-(methylethyl)-2-oxoethyl]carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-1-{[1-(triphenylmethyl)imidazol-4-yl]carbonyl}-3-(1,2,3,4-tetrahydroisoquinolyl)-N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-(methylethyl)-2-oxoethyl]carboxamide(337969-56-9)
• EPA Substance Registry System: (2S)-1-{[1-(triphenylmethyl)imidazol-4-yl]carbonyl}-3-(1,2,3,4-tetrahydroisoquinolyl)-N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-1-(methylethyl)-2-oxoethyl]carboxamide(337969-56-9)

Safety Data

• Hazardous Substances Data: 337969-56-9(Hazardous Substances Data)

Upstream product

• 337969-48-9 tert-butyl (3S)-3-{N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-hydroxy-1-(methylethyl)ethyl]carbamoyl}-1,2,3,4-tetrahydroisoquinoline-2-carboxylate 
• 251540-54-2 {1-[(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-hydroxy-methyl]-2-methyl-propyl}-carbamic acid tert-butyl ester 
• 251540-53-1 2-tert-Butyl-1,3,4-oxadiazole 
• 191103-80-7 1H-1-triphenylmethylimidazole-4-carboxylic acid 
• 76-83-5 trityl chloride 
• 42826-42-6 pivalohydrazide 
• 598-98-1 Methyl pivalate 
• 337969-54-7 (2S)-1-[1-(triphenylmethyl)imidazol-4-yl]carbonyl-3-(1,2,3,4-tetrahydroisoquinolyl)-N-[(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-hydroxy-1-(methylethyl)ethyl]carboxamide 

Relevant articles and documents

Development of orally active nonpeptidic inhibitors of human neutrophil elastase

5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an α-keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-l(F), 11d,e,k(H), 21d,e,k(F), and 21d,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure -activity relationships (SARs) are discussed.